The COVIDâ19 pandemic represents an unparalleled global public health crisis. Despite concerted research endeavours, the repertoire of effective treatment options remains limited. However, neutralisingâantibodyâbased therapies hold promise across an array of practices, encompassing the prophylaxis and management of acute infectious diseases. Presently, numerous investigations into COVIDâ19âneutralising antibodies are underway around the world, with some studies reaching clinical application stages. The advent of COVIDâ19âneutralising antibodies signifies the dawn of an innovative and promising strategy for treatment against SARSâCoVâ2 variants. Comprehensively, our objective is to amalgamate contemporary understanding concerning antibodies targeting various regions, including receptorâbinding domain (RBD), nonâRBD, host cell targets, and crossâneutralising antibodies. Furthermore, we critically examine the prevailing scientific literature supporting neutralising antibodyâbased interventions, and also delve into the functional evaluation of antibodies, with a particular focus on in vitro (vivo) assays. Lastly, we identify and consider several pertinent challenges inherent to the realm of COVIDâ19âneutralising antibodyâbased treatments, offering insights into potential future directions for research and development.